Experimental stroke drug NCS-01 enters human safety trials

NCT ID NCT03915431

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests whether a new drug called NCS-01 is safe for people who have had a stroke. Sixteen patients will receive the drug within 48 hours of their stroke. The main goal is to check for side effects, not to see if the drug works. This is a first step to see if larger studies are possible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NCS-01

What this could lead to

If safe, this could pave the way for a new treatment to reduce brain damage after a stroke.

What could go wrong

This is a very early, small study (16 people) focused only on safety. It is not designed to prove the drug works, and many early-stage treatments fail to show benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Miami

    Miami, Florida, 33136, United States